Clinical ProgressETNB is well-positioned with pegozafermin as a potentially best-in-class compound based on the drug’s competitive efficacy.
Clinical TrialsPhase 3 NASH timelines remain on track, and Phase 3 SHTG data are expected, indicating progress in their clinical trials.
Market DifferentiationNVO's discontinuation of zalfermin supports the view that not all FGF21 analogs are created equal, highlighting the positive differentiation for ETNB's pegoza.